TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 272-274

  Zainuddin, Norafiza ^a   Murray, Fiona ^b   Kanduri, Meena ^b   Gunnarsson, Rebeqa ^c   Smedby, Karin E ^d   Enblad, Gunilla ^a   Jurlander, Jesper ^e   Juliusson, Gunnar ^c   Rosenquist, Richard ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Rigshospitalet   (Denmark)

Author keywords

17p deletion; Chronic lymphocytic leukemia; Prognosis; TP53 mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATION RATE; NONSENSE MUTATION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78751702338     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.023     Document Type: Article

References (10)

1. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343(26):1910-1916.
2. Zenz T., Krober A., Scherer K., Habe S., Buhler A., Benner A., et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112(8):3322-3329.
3. Dicker F., Herholz H., Schnittger S., Nakao A., Patten N., Wu L., et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009, 23(1):117-124.
4. Rossi D., Cerri M., Deambrogi C., Sozzi E., Cresta S., Rasi S., et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009, 15(3):995-1004.
5. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V., et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009.
6. Zenz T., Habe S., Denzel T., Mohr J., Winkler D., Buhler A., et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009, 114(13):2589-2597.
7. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood 2008, 111(12):5446-5456.
8. Gunnarsson R., Staaf J., Jansson M., Ottesen A.M., Goransson H., Liljedahl U., et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia - a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008, 47(8):697-711.
9. Zainuddin N., Berglund M., Wanders A., Ren Z.P., Amini R.M., Lindell M., et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 2009, 33(1):60-66.
10. Best O.G., Gardiner A.C., Davis Z.A., Tracy I., Ibbotson R.E., Majid A., et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009, 23(1):212-214.